Chafic Karam

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Vera Bril, Artur Drużdż, Julian Großkreutz et al. · The Lancet Neurology · 2023 · 227 citations

Clinical Trials, Generalised Myasthenia Gravis, Pharmacotherapy +3

Trial of Intravenous Immune Globulin in Dermatomyositis

Rohit Aggarwal, Christina Charles‐Schoeman, Joachim Schessl et al. · New England Journal of Medicine · 2022 · 181 citations · Full text

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Michael G. Hanna, Umesh A. Badrising, Olivier Benvéniste et al. · The Lancet Neurology · 2019 · 128 citations · Full text

Autoimmune Disease, Immunology, Placebo-controlled Phase 2B +4